Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
KZIA 
Kazia Therapeutics Ltd ADR (KZIA)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
07/07/2025: KZIA (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
1 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $15.02
1 Year Target Price $15.02
| 0 | Strong Buy |
| 1 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -39.01% | Avg. Invested days 24 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Star Rating | Upturn Advisory Performance  3.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 07/07/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 9.18M USD | Price to earnings Ratio - | 1Y Target Price 15.02 |
Price to earnings Ratio - | 1Y Target Price 15.02 | ||
Volume (30-day avg) 1 | Beta 2.48 | 52 Weeks Range 2.86 - 79.00 | Updated Date 07/6/2025 |
52 Weeks Range 2.86 - 79.00 | Updated Date 07/6/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -29.41 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Earnings Date
Report Date 2025-06-10 | When - | Estimate - | Actual -12.3 |
Profitability
Profit Margin - | Operating Margin (TTM) -42029.54% |
Management Effectiveness
Return on Assets (TTM) -85.55% | Return on Equity (TTM) -3891.64% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 7252969 | Price to Sales(TTM) 3.67 |
Enterprise Value 7252969 | Price to Sales(TTM) 3.67 | ||
Enterprise Value to Revenue 4.78 | Enterprise Value to EBITDA -0.71 | Shares Outstanding 1359620 | Shares Floating 422580635 |
Shares Outstanding 1359620 | Shares Floating 422580635 | ||
Percent Insiders 10.09 | Percent Institutions 8.22 |
Upturn AI SWOT
Kazia Therapeutics Ltd ADR
Company Overview
History and Background
Kazia Therapeutics Ltd is an Australian oncology-focused drug development company, established in 2009. It focuses on developing novel therapies for cancer. Originally named Novogen, it rebranded to Kazia Therapeutics.
Core Business Areas
- Oncology Drug Development: Focuses on developing and commercializing innovative therapies for cancer, with a pipeline of clinical and pre-clinical stage assets.
Leadership and Structure
Kazia Therapeutics is led by a management team with experience in drug development and commercialization. The company has a board of directors providing oversight and guidance.
Top Products and Market Share
Key Offerings
- Paxalisib: A PI3K/Akt/mTOR pathway inhibitor in clinical development for glioblastoma (GBM) and other cancers. While not yet approved and therefore having no revenue, competitors include Merck's Temodar, and other therapies used in GBM treatment.
- Cantrixil: An oral formulation under evaluation in ovarian cancer. Phase 1 clinical trials have been completed. There are no revenue or users yet. Competitors include standard chemotherapy regimens for ovarian cancer.
Market Dynamics
Industry Overview
The oncology market is large and growing, driven by an aging population and advancements in cancer diagnostics and treatment. There's high demand for novel therapies with improved efficacy and safety profiles.
Positioning
Kazia Therapeutics is a small-cap biotech company focused on niche oncology markets. Its competitive advantage lies in its targeted therapies and clinical development expertise.
Total Addressable Market (TAM)
The global glioblastoma market is estimated at billions of USD. Kazia's position is as a developer of a novel treatment option, aiming to capture a share of this large market.
Upturn SWOT Analysis
Strengths
- Novel drug candidates with potential for clinical benefit
- Experienced management team
- Focus on specific cancer subtypes
- Clinical data showing promise in specific cancer indications
Weaknesses
- Limited financial resources compared to larger pharmaceutical companies
- Drug development is high-risk and time-consuming
- Reliance on clinical trial success
- Currently no approved products on the market
Opportunities
- Potential for regulatory approval of Paxalisib and Cantrixil
- Partnerships with larger pharmaceutical companies
- Expansion into new cancer indications
- Advancements in personalized medicine
Threats
- Clinical trial failures
- Competition from other cancer therapies
- Regulatory hurdles
- Intellectual property challenges
Competitors and Market Share
Key Competitors
- MRK
- BMY
- NVS
Competitive Landscape
Kazia Therapeutics competes with larger pharmaceutical companies in the oncology market. Its advantage lies in its niche focus and novel therapies, but it faces significant challenges in terms of resources and market access. Kazia currently has no approved drugs on the market and therefore no market share.
Growth Trajectory and Initiatives
Historical Growth: Historical growth is characterized by clinical trial advancements and pipeline progress.
Future Projections: Future growth is highly dependent on the successful development and commercialization of Paxalisib and Cantrixil. Analyst estimates vary widely depending on clinical trial outcomes.
Recent Initiatives: Recent initiatives include advancing Paxalisib in clinical trials for GBM and exploring new indications. They are also continuing to advance Cantrixil in Ovarian Cancer.
Summary
Kazia Therapeutics is a development-stage biotech company with promising oncology assets, particularly Paxalisib. Their success hinges on clinical trial outcomes and regulatory approvals. While their market cap is currently low, they face significant competition and financial constraints. Positive clinical data could dramatically improve their prospects.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company website
- SEC filings
- Analyst reports
- Market research reports
Disclaimers:
This analysis is for informational purposes only and should not be considered investment advice. The information provided is based on publicly available data and analyst estimates, which are subject to change. Investing in biotech companies involves significant risks, including clinical trial failures and regulatory hurdles.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Kazia Therapeutics Ltd ADR
Exchange NASDAQ | Headquaters Sydney, NSW, Australia | ||
IPO Launch date 1999-01-06 | CEO, MD & Director Dr. John Edwin Friend II, M.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees - | |
Full time employees - | |||
Kazia Therapeutics Limited, together with its subsidiaries, operates as an oncology-focused biotechnology company in South Korea. Its lead development candidate is paxalisib, a small molecule, brain-penetrant inhibitor of the phosphoinositide-3-kinase (PI3K)/AKT/mammalian target of rapamycin (mTOR) pathway, which is in Phase 3 clinical trial, for the treatment of glioblastoma, isocitrate dehydrogenase-mutant glioma, diffuse intrinsic pontine glioma, atypical teratoid/rhabdoid tumor, brain metastases, primary central nervous system (CNS) lymphoma, triple negative breast cancer, and ovarian cancer. The company also develops EVT801, a small-molecule selective inhibitor of vascular endothelial growth factor receptor 3, which is in Phase 1 clinical trial, to treat advanced solid tumors. It has collaborations with the Australian and New Zealand Children's Haematology/Oncology Group, OIMR Berghofer Medical Research Institute, Genentech Inc., Global Coalition for Adaptive Research, Vivesto AB, Simcere Pharmaceutical Group Ltd, Evotec SE, and Sovargen Co., Ltd. The company was formerly known as Novogen Limited and changed its name to Kazia Therapeutics Limited in November 2017. Kazia Therapeutics Limited was incorporated in 1994 and is based in Sydney, Australia.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.